Acarix'' share issue well oversubscribed in connection with the initial public offering on Nasdaq First North Premier in Stockholm

ID: 1474676
recent pressrelease next pressrelease

(Thomson Reuters ONE) -

Press Release December 8, 2016


Acarix'' share issue well oversubscribed in connection with the initial public
offering on Nasdaq First North Premier in Stockholm

Acarix AB ("Acarix" or the "Company") is pleased to announce that it has
successfully raised SEK 140 million before transaction costs through a well-
oversubscribed share issue in connection with the initial public offering
listing on Nasdaq First North Premier (the "Offering"). The Offering was
directed to institutional and professional investors as well as to the public in
Sweden and Denmark. Due to the large interest, allotment of new shares has been
made to around 1,200 new shareholders among 3,000 applicants.

First day of trading of the Company''s shares on Nasdaq First North Premier in
Stockholm is expected to be December 19, 2016.

Acarix is a Swedish/Danish commercial stage medical device company, specialised
in non-invasive, non-radiation acoustic rule-out of Coronary Artery Disease
(CAD). The funds raised will primarily be used to execute the Company''s
commercialization strategy and anticipated launch in Q2, 2017, with initial
focus on Germany, UK, Sweden and Denmark for the already CE-marked

The subscription period for Acarix'' Offering expired on December 7, 2016.
Already before the subscription period began, a number of existing and new
investors, including Puhua Jingxin Guzhou Health Management Partnership, the
Bank of Åland''s Fund Management Division, Ålandsbanken Abp, Sverker Martin-
Löf, Carl-Olof By, and Rolf Börjesson through the company Industrial Development

Partners AB, and Lars Holmqvist, former CEO of Dako and later Senior Vice
President of Agilent, had committed to subscribe for shares in the Offering
totalling just over SEK 120 million or approximately 86 per cent of the
Offering. These investors were then given priority when shares were allocated.
However, the overall goal of the Offering remained to obtain a broad
distribution of shares among the public in Sweden and Denmark in order to allow
regular and liquid trading of Acarix'' shares on Nasdaq First North Premier.

Vator Securities acted as global co-ordinator and sole bookrunner in the initial
public offering.

After the new share issue has been registered at Bolagsverket (the Swedish
Companies Registration Office), the total number of shares in Acarix will
increase by 7,960,000 to 23,027,376 representing an increase of the share
capital and votes of 53 per cent.


Vator Securities is the financial advisor and Baker & McKenzie is the legal
advisor to the Company in connection with the new share issue and initial public
offering on Nasdaq First North Premier. Wildeco is the Certified Advisor to the

For more information, please contact:

Søren Rysholt Christiansen, CEO, Acarix
E-mail: dksrc(at)
Phone: +45 2777 1112

Notes to editors:
Acarix , CADScor®System and cardiac sound measurement

Acarix was established in 2009 as a spinout company from Coloplast A/S. Since
2010 key investors Seed Capital (DK) and Sunstone Life Science Ventures (DK)
have financed the development of the company and supported it towards market
introduction. While some founders remain in the company, Acarix has attracted a
highly experienced management team who have held senior positions in
international medical device companies - CEO Søren Rysholt Christiansen with
ELOS Medtech, GN ReSound and Cook Medical.

Acarix'' CADScor(®)System is based on pioneering research at Aalborg University.
It has long been known that both cardiac contraction movement and turbulent flow
can generate sound. Contraction related sounds are in lower frequency, whereas
turbulent sounds in the streaming blood caused by partial obstruction (stenosis)
in the coronary arteries are of higher frequencies. The detection of these
murmurs is delicate, since the energy of the murmurs is very weak. Detecting and
recording the coronary murmurs requires not only an advanced sensor but also
means for proper attachment to the skin above the heart to optimize the recorded
signal and to avoid external noise.

The Acarix CADScor(®)System has been designed to be an all-in-one system in the
sense that the heart signal will be recorded, processed and displayed as a
patient specific score, the CAD-score, on the device screen.

The CADScor(®)System contains the necessary electronics to instruct
professionals during use and guide the patient through the recording periods.
The system also contains a docking station for daily qualification of the
sensor. Further the system integrates with an adhesive patch for locking the
CADScor(®) sensor to a fixed position above the heart during the recording.

The software embedded in The Acarix CADScor(®)System ensures that adequate
recording conditions are controlled at every examination, whether performing
your examinations in a quiet clinical settings or at busy GP clinics, at high
altitudes (>95% coverage) or on the move.

The CADScor(®)System is CE Marked (by TÜV in 2015) and due for commercial launch
in 2017.

See more at

Important information

This announcement is not and does not form a part of any offer for sale of
securities. Copies of this announcement are not being made and may not be
distributed or sent into the United States, Australia, Canada, Hong Kong, Japan,
South Africa or any other jurisdiction in which such distribution would be
unlawful or would require registration or other measures. The securities
referred to in this announcement

have not been and will not be registered under the U.S. Securities Act of 1933,
as amended (the "Securities Act"), and accordingly may not be offered or sold in
the United States absent registration or an exemption from the registration
requirements of the Securities Act and in accordance with applicable U.S. state
securities laws. The company does not intend to register any offering in the
United States or to conduct a public offering of securities in the United

The offering of securities referred to in this announcement has been made by
means of a prospectus. This announcement is not a prospectus for the purposes of
Directive 2003/71/EC (together with any applicable implementing measures in any
Member State, the "Prospectus Directive"). Investors should not invest in any
securities referred to in this announcement except on the basis of information
contained in the aforementioned prospectus. In any EEA Member State other than
Sweden that has implemented the Prospectus Directive, this communication is only
addressed to and is only directed at qualified investors in that Member State
within the meaning of the Prospectus Directive, i.e., only to investors who can
receive the offer without an approved prospectus in such EEA Member State.

This communication is only being distributed to and is only directed at persons
in the United Kingdom that are (i) investment professionals falling within
Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005, as amended (the "Order") or (ii) high net worth entities,
and other persons to whom this announcement may lawfully be communicated,
falling within Article 49(2)(a) to (d) of the Order (all such persons together
being referred to as "Relevant Persons"). This communication must not be acted
on or relied on by persons who are not Relevant Persons. Any investment or
investment activity to which this communication relates is available only to
Relevant Persons and will be engaged in only with Relevant Persons. Persons
distributing this communication must satisfy themselves that it is lawful to do

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as "believe," "expect," "anticipate,"
"intends," "estimate," "will," "may," "continue," "should" and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although the company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors that are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward- looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date, and are
subject to change without notice.

PR 2016-12-08 en:

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Acarix AB via GlobeNewswire

More information:
http:// http://www.e

Keywords (optional):

Company information / Profile:

PressRelease by


PressContact / Agency:

published by: hugin
print pressrelease  send to a friend  

Date: 12/08/2016 - 10:00
Language: English
News-ID 1474676
Character count: 6838
Firma: Acarix AB
Ansprechpartner: Feedback to about Pressrelease-id:
Stadt: Malmö


Number of hits: 419


Direct Link to this PressRelease:

We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease

All members: 8 020
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 52

Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.